Xgeva and Retacrit drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Xgeva (denosumab) and Retacrit (epoetin alfa-epbx). Common drug interactions include asthenia among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Xgeva and Retacrit. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Xgeva?

Xgeva has active ingredients of denosumab. It is often used in breast cancer. eHealthMe is studying from 37,717 Xgeva users. Check the latest studies of Xgeva.

What is Retacrit?

Retacrit has active ingredients of epoetin alfa-epbx. eHealthMe is studying from 2,196 Retacrit users. Check the latest studies of Retacrit.

On Jul, 05, 2026

31 people who take Xgeva and Retacrit together, and have interactions are studied.

What are the common drug interactions of Xgeva and Retacrit, by gender? *:

female:

Asthenia (weakness)
Alopecia (absence of hair from areas of the body)
Circadian rhythm sleep disorder (family of sleep disorders affecting, among other things, the timing of sleep)
Dry skin
Insomnia (sleeplessness)
Nervousness
Psychiatric symptom
Somnolence (a state of near-sleep, a strong desire for sleep)
Terminal insomnia (a sleep disorder in which there is an inability to fall asleep or to stay asleep as long as desired)
Hypotension (abnormally low blood pressure)

male:

Diarrhoea
Fatigue (feeling of tiredness)
Chest discomfort
Constipation
Decreased appetite
Depression
Drug intolerance (drug sensitivity)
Dyspnoea (difficult or laboured respiration)
Full blood count decreased
Impaired gastric emptying

What are the common drug interactions of Xgeva and Retacrit, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Death
Metastases to spine (cancer spreads to spine)
Metastatic neoplasm (spreadable cancer tumour)
Pain
Retroperitoneal neoplasm metastatic (tumour between peritoneum and the posterior abdominal wall spreads out)
Fatigue (feeling of tiredness)
Mobility decreased (ability to move is reduced)
Palpitations (feelings or sensations that your heart is pounding or racing)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
White blood cell count decreased

60+:

Asthenia (weakness)
Alopecia (absence of hair from areas of the body)
Anaemia (lack of blood)
Death
Dizziness
Injection site pain
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Fatigue (feeling of tiredness)
Hypertension (high blood pressure)
Nosocomial infection (infection from hospital)

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 16 people, 51.61%
Kidney Stones: 4 people, 12.90%
Diabetes: 4 people, 12.90%
Pain: 3 people, 9.68%
Prostate Cancer: 2 people, 6.45%
Neuropathy Peripheral (surface nerve damage): 2 people, 6.45%
Nephrogenic Anaemia (anaemia due to kidney disease): 2 people, 6.45%
Nausea (feeling of having an urge to vomit): 2 people, 6.45%
Immunodeficiency Common Variable: 2 people, 6.45%
Chronic Kidney Disease: 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Xgeva and Retacrit?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously